Nicotinamide Adenine Dinucleotide Augmentation in Overweight or Obese Middle-Aged and Older Adults: A Physiologic Study
Authors' conclusion
MIB-626 administration in overweight or obese, middle-aged and older adults safely increased circulating NAD levels, and significantly reduced total LDL and non-HDL cholesterol, body weight, and diastolic blood pressure. These data provide the rationale for larger trials to assess the efficacy of NAD augmentation in improving cardiometabolic outcomes in older adults.
Study context
- Population
- Overweight or obese adults aged ≥45 years at risk for age-related conditionsrandomized 2:1
- Participants
- 30 participants
- Comparison
- MIB-626 vs placebo
Methodological detailsplacebo-controlled, 2:1 randomisation, physiologic study
- Placebo-controlled
- 2:1 randomisation
- Physiologic study
Primary result
As reported in the abstract
Physiologic effects (changes over 28 days)
Each group vs placeboDifference (body weight), kg (CI)P value
MIB-626
−1.9(−3.3 to −0.5)
P = 0.008Each group vs placeboDifference (diastolic BP), mmHg (CI)P value
MIB-626
−7.01(−13.44 to −0.59)
P = 0.034Each group vs placeboEstimate (CI)P value
MIB-626
difference (total cholesterol) −26.89 mg/dL(−44.34 to −9.44)
P = 0.004MIB-626
difference (LDL-C) −18.73 mg/dL(−31.85 to −5.60)
P = 0.007Further findings
Muscle strength, fatigability, aerobic capacity, stair-climbing power
- Changes did not differ significantly between groups
Insulin sensitivity, hepatic and intra-abdominal fat
- Did not change in either group
Safety
- Adverse events were similar between groups
Original publication
Nicotinamide Adenine Dinucleotide Augmentation in Overweight or Obese Middle-Aged and Older Adults: A Physiologic Study. J Clin Endocrinol Metab. Published 6 February 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →